Özgür Mete

department of pathology

H指数:59

被引数:1.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Comprehensive Genomic Analysis in Hereditary Adrenal and Extra-Adrenal Paragangliomas

遗传性肾上腺内和肾上腺外副神经节瘤的全面基因组分析

Endocrine Pathology

IF14.7

2026-08-240

OAAI

Current Concepts in Pituitary Pathology

垂体病理学的新进展

Modern Pathology

IF5.5

2026-08-040

PRE

Immunohistochemical and Genetic Evidence of Lynch Syndrome-Related Well-Differentiated Pancreatic Neuroendocrine Tumor in Association with Peliosis of the Non-Tumorous Islets and Ductulo-Insular Complexes: An Expansion of Endocrine Manifestations of Lynch Syndrome

与Lynch综合征相关的高分化胰腺神经内分泌肿瘤与非肿瘤性胰岛和导管-胰岛复合体的骨盆病相关的免疫组织化学和遗传学证据: Lynch综合征的内分泌表现的扩展

Endocrine Pathology

IF14.7

2026-01-310

PRE

Composite Gangliocytoma/Neuroma and Neuroendocrine Tumor (CoGNET) of the Duodenum: An Image in Endocrine Pathology Exploring Patterns of Biomarker Expression in Tumor Elements

十二指肠的复合神经节细胞瘤/神经瘤和神经内分泌肿瘤 (CoGNET): 内分泌病理学图像，探索肿瘤元素中生物标志物表达的模式

Endocrine Pathology

IF14.7

2026-01-150

PRE

The evolving roles of pathologists in paragangliomas and pheochromocytomas

神经内分泌肿瘤和嗜铬细胞瘤中病理学家角色的演变

Virchows Archiv

IF3.1

2025-12-230

PRE

Avoiding overdiagnosis of parathyroid carcinoma

避免甲状旁腺癌的过度诊断

Virchows Archiv

IF3.1

2025-11-140

OAAI

Revisionist history uncovers a simplified molecular-based classification of differentiated thyroid cancer

修正主义历史揭示了基于分子的简化的分化型甲状腺癌分类

The Journal of Pathology

IF5.2

2025-08-050

OAAI

Clinical integration and application of the 2022 WHO pituitary tumor classification

2022年WHO垂体肿瘤分类的临床整合与应用

NEURO-ONCOLOGY ADVANCES

IF4.1

2025-07-011

OAAI

Identification of Specific Biomarkers for Anaplastic Thyroid Carcinoma Through Spatial Transcriptomic and Immunohistochemical Profiling

通过空间转录组学和免疫组化分析鉴定未分化甲状腺癌的特异性生物标志物

ENDOCRINE PATHOLOGY

IF14.7

2025-04-171

PRE

Refining NTRK Fusion Detection in Papillary Thyroid Carcinoma Through Pan-TRK Immunohistochemistry and Histopathologic Features

通过泛-TRK免疫组化与组织病理学特征优化乳头状甲状腺癌中NTRK融合的检测

ENDOCRINE PATHOLOGY

IF14.7

2025-03-180

PRE

Distant Metastatic Sites from Follicular Cell Derived Thyroid Carcinoma Show Differential Enrichment of Molecular Alterations: A Series of 156 Cases

LABORATORY INVESTIGATION

IF4.2

2025-03-010

PRE

Morphological Indicators of DICER1 Mutations May Guide Somatic and Germline Testing

THYROID

IF6.7

2025-01-010

PRE

Insights into Biologic Evolution of Grade 3 Neuroendocrine Tumors Reflect Classification Challenges

ENDOCRINE PATHOLOGY

IF14.7

2024-12-120

PRE

Consensus Statement: Recommendations on Actionable Biomarker Testing for Thyroid Cancer Management (Nov, 10.1007/s12022-024-09836-x, 2024)

ENDOCRINE PATHOLOGY

IF14.7

2024-12-060

OAAI

Recent progress in the pathologic classification of pheochromocytomas and paragangliomas

BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM

IF6.1

2024-12-011

PRE

Lutetium 177 Radionuclide Lutetium 177 Radionuclide Therapy-Induced Proliferative Arrest in a Therapy-Induced Proliferative Arrest in a Metastatic High-Grade Rectal Metastatic High-Grade Rectal Neuroendocrine Tumor Neuroendocrine Tumor

MAYO CLINIC PROCEEDINGS

IF6.7

2024-12-010

PRE

Cauda Equina Neuroendocrine Tumors with Ganglioneuromatous Elements are Best Classified as Composite Gangliocytoma/Neuroma and Neuroendocrine Tumor (COGNET)

ENDOCRINE PATHOLOGY

IF14.7

2024-11-271

PRE

Multilineage Pituitary Neuroendocrine Tumors Expressing TPIT and SF1: A Clinicopathological Series of Six Tumors

表达TPIT和SF1的多系垂体神经内分泌肿瘤: 六种肿瘤的临床病理系列

ENDOCRINE PATHOLOGY

IF14.7

2024-11-230

PRE

Multidisciplinary Canadian consensus on the multimodal management of high-risk and radioactive iodine-refractory thyroid carcinoma

FRONTIERS IN ONCOLOGY

IF3.3

2024-11-042

OAAI

Granulation Patterns of Functional Corticotroph Tumors Correlate with Tumor Size, Proliferative Activity, T2 Intensity-to-White Matter Ratio, and Postsurgical Early Biochemical Remission

ENDOCRINE PATHOLOGY

IF14.7

2024-07-240

OAAI

Özgür Mete

个人简介

教育背景

工作经历

荣誉奖项

研究方向